Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » The Scan » Not Much of a Choice, Anyway

Not Much of a Choice, Anyway

Feb 24, 2009

With credit tight and investors skittish, a hostile takeover of Genentech by Roche might not be that big of a deal, says an article in the San Jose Mercury News. And in any case, it's possible Genentech employees won't have many options these days when it comes to finding other jobs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Treatment for Rapid Aging

NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.

AstraZeneca, Oxford Announce Results Suggesting High Efficacy of Vaccine

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

Criticism Leads to Review of Paper

ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.

PLOS Papers on SARS-CoV-2 Phylogenies, Swiss Influenza Spread, Infant Meningitis in Ethiopia

In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.

Dec
15
Featured Webinar

Case Study: Deployment of High-Throughput SARS-CoV-2 Testing at UC Davis

Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.

What's Popular?

In Drug Discovery & Development

  1. PMC Report Outlines Strong Growth, Future Challenges for Personalized Medicine Industry

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.